Clinical Trials on Nasopharyngeal Melanoma

Total 4065 results

F. Stephen Hodi, MD
MedImmune LLC

Completed

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Metastatic Melanoma

United States
The Christie NHS Foundation Trust
National Institute for Health Research, United Kingdom

Terminated

TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment (METILDA)

Metastatic Melanoma

United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma

Advanced Melanoma

China
Linkoeping University
Karolinska Institutet; Region Östergötland; Region Stockholm; Kronoberg County... and other collaborators

Completed

Diagnostic Precision of the AI Tool Dermalyzer to Identify Malignant Melanomas in Subjects Seeking Primary Care for Melanoma-suspected Cutaneous Lesions (AI-DSMM)

Malignant Melanoma

Sweden
Biocad

Active, not recruiting

Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma (OBERTON)

Melanoma | Melanoma Metastatic

Russian Federation, Belarus
Netherlands Working Group on Immunotherapy of Oncology
Hoffmann-La Roche; Amsterdam UMC, location VUmc; The Netherlands Cancer Institute

Terminated

Vemurafenib Plus Cobimetinib in Metastatic Melanoma (REPOSIT)

Metastatic Melanoma

Netherlands
Ludwig Institute for Cancer Research

Terminated

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Malignant Melanoma

Belgium
Ludwig Institute for Cancer Research
Cancer Research Institute (CRI)

Completed

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

Malignant Melanoma

United States
Ludwig Institute for Cancer Research

Terminated

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Malignant Melanoma

Belgium
CHU de Reims

Completed

Molecular Characterization of Advanced Stage Melanoma by Blood Sampling (MELCIRC)

Metastatic Melanoma

France
Bristol-Myers Squibb

Completed

Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database

Advanced Melanoma

Germany
University of Utah

Completed

Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

Melanoma (Skin)

United States
4SC AG

Completed

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE)

Malignant Melanoma

Germany, Italy
Hospices Civils de Lyon

Completed

Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma (IMMUNONIVO)

Metastatic Melanoma

France
Hospices Civils de Lyon

Completed

Pre Transplantation Melanoma (MPG)

Malignant Melanoma

France
Hoffmann-La Roche

Completed

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

Malignant Melanoma

United States, Australia, Brazil, Spain, South Africa, Ukraine, Bosnia and Herzegovina
Nektar Therapeutics
ImaginAb, Inc.

Withdrawn

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

Metastatic Melanoma

United States
OncoImmune, Inc.
National Cancer Institute (NCI); Huntsman Cancer Institute

Withdrawn

CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI)

Metastatic Melanoma

United States
Ultimovacs ASA
Oslo University Hospital

Active, not recruiting

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Malignant Melanoma

Norway
University of Kansas Medical Center

Completed

Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma

Malignant Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
BioNTech US Inc.
Apexigen, Inc.

Terminated

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

Metastatic Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Inge Marie Svane

Completed

Vemurafenib and TIL Therapy for Metastatic Melanoma

Metastatic Melanoma

Denmark
OrienGene Biotechnology Ltd.

Unknown

A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients

Melanoma (Skin)

China
A.J.M. van den Eertwegh

Completed

Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

Cutaneous Melanoma
University of Basel
University Hospital, Basel, Switzerland

Completed

Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma

Malignant Melanoma
Nantes University Hospital
UMR892

Completed

Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study (MelSort)

Metastatic Melanoma

France
CHU de Reims

Unknown

Molecular Characterization of Primary Mucosal Melanoma (MELMUQ)

Mucosal Melanoma

France
Celgene
Prologue Research International

Completed

Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

Malignant Melanoma

United States
University of Regensburg

Unknown

Immune Monitoring in Metastatic Melanoma

Metastatic Melanoma

Germany
Eli Lilly and Company

Completed

An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma

Malignant Melanoma

United States
Providence Health & Services
Providence Cancer Center, Earle A. Chiles Research Institute; Galectin Therapeutics...

Completed

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Cliniques universitaires Saint-Luc- Université...

Terminated

Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma

Metastatic Melanoma

Belgium
Milton S. Hershey Medical Center

Completed

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

Malignant Melanoma

United States
Osaka University
Merck Sharp & Dohme LLC; ISHIHARA SANGYO KAISHA,LTD. Japan

Unknown

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII

Advanced Melanoma

Japan
Skin Analytics Limited

Completed

Melanoma Image Analysis Algorithm (MIAA) Validation Study

Malignant Melanoma

United Kingdom
Dartmouth-Hitchcock Medical Center

Terminated

Metronomic Therapy in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
University of Arizona

Terminated

A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

Malignant Melanoma

United States
Duke University

Completed

Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

Unresectable Melanoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

Melanoma (Skin)

United States
Western Regional Medical Center

Terminated

Interleukin-2 in Metastatic Melanoma

Melanoma Metastatic

United States
Peking University Cancer Hospital & Institute

Unknown

A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

Advanced Melanoma

China
American Regent, Inc.

Completed

Taxoprexin Treatment for Advanced Skin Melanoma

Metastatic Melanoma
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

Malignant Melanoma

China
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Participants With Metastatic Melanoma

Malignant Melanoma

Canada, Spain, United Kingdom, Hungary, Australia, Austria, Belgium, Ecuador, Estonia, Finland, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Slovenia, Sweden, Turkey, Brazil, India, Germany, Bosnia and Herzegovina and more
Melanoma Research Foundation Breakthrough Consortium
Genentech, Inc.

Terminated

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Melanoma | Metastatic Melanoma

United States
National Cancer Institute (NCI)

Withdrawn

In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma

Metastatic Melanoma
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim

Melanoma (Skin)
New England Retina Associates

Completed

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

Choroidal Melanoma

United States

3

Subscribe